Jiangsu Sihuan Bioengineering Co Ltd
SZSE:000518
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/OCF
Price to Operating Cash Flow (P/OCF) ratio compares a company`s market value to the cash it generates from its core operations.
Price to Operating Cash Flow (P/OCF) ratio compares a company`s market value to the cash it generates from its core operations.
Valuation Scenarios
If P/OCF returns to its 3-Year Average (376.2), the stock would be worth ¥30.95 (964% upside from current price).
| Scenario | P/OCF Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 35.4 | ¥2.91 |
0%
|
| 3-Year Average | 376.2 | ¥30.95 |
+964%
|
| 5-Year Average | 191.9 | ¥15.79 |
+443%
|
| Industry Average | 38.2 | ¥3.14 |
+8%
|
| Country Average | 18.3 | ¥1.5 |
-48%
|
Forward P/OCF
Today’s price vs future operating cash flow
Peer Comparison
| Market Cap | P/OCF | P/E | ||||
|---|---|---|---|---|---|---|
| CN |
J
|
Jiangsu Sihuan Bioengineering Co Ltd
SZSE:000518
|
3B CNY | 35.4 | -27.7 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | -211 714.7 | -160 127.7 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
373.6B USD | 19.3 | 87.6 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
186.6B USD | 17.7 | 22.8 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
162.4B USD | 16.3 | 19.2 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | -531.3 | -533.6 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
108.6B USD | 29.6 | 27.2 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
74.7B USD | 14.9 | 16.5 | |
| NL |
|
argenx SE
XBRU:ARGX
|
41.3B EUR | 119.6 | 37.4 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | -85.8 | -61.8 | |
| AU |
|
CSL Ltd
ASX:CSL
|
60B AUD | 11.4 | 29.6 |
Market Distribution
| Min | 0.2 |
| 30th Percentile | 9.8 |
| Median | 18.3 |
| 70th Percentile | 36.5 |
| Max | 266 666.7 |
Other Multiples
Jiangsu Sihuan Bioengineering Co Ltd
Glance View
Jiangsu Sihuan Bioengineering Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceutical products. The company is headquartered in Wuxi, Jiangsu and currently employs 254 full-time employees. The Company’s main products include interleukin, erythropoietin (EPO), granulocyte colony-stimulating factor (G-CSF), tablets, bulk drugs, infusion glass bottles, soft bag infusion, syrup and healthcare products, among others. The firm is also engaged in landscape engineering, maintenance projects, the sale of nursery stocks and other businesses. The firm distributes its products in domestic market and to overseas markets.
